Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03850574 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute
Refractory AML
Relapsed Adult AML
Myelodysplastic Syndrome With Excess Blasts-2
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Tuspetinib
DRUG: Venetoclax Oral Tablet
DRUG: Azacitidine for Intravenous Infusion

Sponsor

Aptose Biosciences Inc.